First detection in Europe of the metallo-β-lactamase IMP-15 in clinical strains of Pseudomonas putida and Pseudomonas aeruginosa

Gilarranz, Raúl; Juan, Carlos; Castillo-Vera, Jane; Chamizo, Francisco; Artiles, Fernando; Álamo, I.; Oliver, Antonio

doi:10.1111/1469-0691.12248

Cited by 30 publications

(27 citation statements)

References 20 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1), was Ͼ99% identical to that of In589, which was detected in an IMP-15-producing P. aeruginosa isolated in Spain (accession no. KC310496) (8). The sequence from nt 6037 to 10882, which contained tnpAorf1-dnaK-uspA-orf2 (Fig.…”

Section: Resultsmentioning

confidence: 99%

Multidrug-Resistant Sequence Type 235 Pseudomonas aeruginosa Clinical Isolates Producing IMP-26 with Increased Carbapenem-Hydrolyzing Activities in Vietnam

Tada

Nhung

Miyoshi‐Akiyama

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Forty clinical isolates of multidrug-resistant Pseudomonas aeruginosa were obtained in a medical setting in Hanoi, Vietnam. Whole genomes of all 40 isolates were sequenced by MiSeq (Illumina), and phylogenic trees were constructed from the single nucleotide polymorphism concatemers. Of these 40 isolates, 24 (60.0%) harbored metallo-␤-lactamase-encoding genes, including bla IMP-15 , bla IMP-26 , bla IMP-51 , and/or bla NDM-1 . Of these 24 isolates, 12 harbored bla IMP-26 and belonged to sequence type 235 (ST235). Escherichia coli expressing bla IMP-26 was significantly more resistant to doripenem and meropenem than E. coli expressing bla IMP-1 and bla IMP-15 . IMP-26 showed higher catalytic activity against doripenem and meropenem than IMP-1 and against all carbapenems tested, including doripenem, imipenem, meropenem, and panipenem, than did IMP-15. These data suggest that clinical isolates of multidrug-resistant ST235 P. aeruginosa producing IMP-26 with increased carbapenem-hydrolyzing activities are spreading in medical settings in Vietnam.

show abstract

Section: Resultsmentioning

confidence: 99%

Multidrug-Resistant Sequence Type 235 Pseudomonas aeruginosa Clinical Isolates Producing IMP-26 with Increased Carbapenem-Hydrolyzing Activities in Vietnam

Tada

Nhung

Miyoshi‐Akiyama

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Studies state higher rate (46%) of VIM positive strains of this group from human specimens [1]. Furthermore, these species have been described as reservoirs for the dissemination of the antibiotic resistance genes to the more pathogenic species such as P. aeruginosa [13][14][15]. P. fulva is the less characterized member of this group which has scarcely been demonstrated as human pathogen.…”

Section: Discussionmentioning

confidence: 99%

Bacteremia in a human caused by an XDR strain of Pseudomonas fulva

Uddin

Roulston

McHugh

et al. 2018

J Infect Dev Ctries

View full text Add to dashboard Cite

This is the first report from Pakistan of a case of bacteremia in a human due to P. fulva, an opportunistic infection with increased risk of a drug resistant phenotype. P. fulva was isolated from blood of a 45 years male admitted in surgical ICU. Isolate was identified by the MALDI-TOF-MS and was extensively drug resistant (XDR) strain. Isolate was found negative for metallo β lactamase (MBL) and extended spectrum β lactamase (ESBL) types by phenotypic and polymerase chain reaction (PCR) assays. It was concluded that P. fulva is an emerging opportunistic pathogen.

show abstract

“…Likewise, the involved mutation-driven and horizontally acquired resistance mechanisms of these strains were previously characterized in detail (19,32). Additionally, the study included a panel of 20 (8,14,17,18,(33)(34)(35). In cases where they were unknown, genotypes were documented through multilocus sequence typing (MLST) using previously described schemes, protocols, available databases, and tools (36; http://pubmlst.org/paeruginosa).…”

Section: Methodsmentioning

confidence: 99%

Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones

Mulet

Cabot

Ocampo-Sosa

et al. 2013

Antimicrob Agents Chemother

106

View full text Add to dashboard Cite

T he increasing prevalence of nosocomial infections produced by multidrug-resistant (MDR) or extensively drug-resistant (XDR) Pseudomonas aeruginosa strains severely compromises the selection of appropriate treatments and is therefore associated with significant morbidity and mortality (1-3). This growing threat results from the interplay of the extraordinary capacity of this pathogen for developing resistance to nearly all available antibiotics by the selection of mutations in chromosomal genes and from the increasing prevalence of transferable resistance determinants, particularly those encoding class B carbapenemases (metallo-␤-lactamases [MBLs]) or extended-spectrum ␤-lactamases (ESBLs), frequently cotransferred with genes encoding aminoglycoside-modifying enzymes (4). Over the last decade, multiple reports have warned about the epidemic dissemination of XDR/ MDR strains in multiple hospitals (5-10). Even more concerning are recent reports which have provided evidence of the existence of MDR/XDR clones of P. aeruginosa disseminated in multiple institutions worldwide, denominated epidemic highrisk clones (11). Among them, are the most widespread (12-18). Moreover, in a recent multicenter study of P. aeruginosa bloodstream infections, we showed that all XDR isolates (10.5% of all isolates) and some MDR isolates belonged to the epidemic high-risk clones, which were not detected among susceptible isolates (19); the specific genetic resistance markers of these clones, which may include multiple combinations of chromosomal mutations and/or horizontally acquired resistance elements, were also described in detail for the first time (19).The global success of bacterial pathogens is expected to be determined by a complex interplay between pathogenicity, epidemicity, and antibiotic resistance (20). The fitness cost of antibiotic resistance mechanisms (21), the existence of regulatory networks interconnecting resistance and virulence (22,23), and natural genetic engineering linking antibiotic resistance determinants and clonal success through genetic capitalism (24) are thought to be the main elements of this intricate equation (25). While the impacts on virulence and fitness of several individual antibiotic resistance mechanisms of P. aeruginosa have been evaluated (26-28), the specific adaptive traits that may explain the global success of epidemic high-risk clones remains unexplored. Since understanding the reasons for the success of these clones could be crucial for designing specific treatment and infection control strategies (29), the objective of this work was to determine the potential underlying biological parameters. For this purpose, using a large collection of well-characterized strains with different resistance profiles from a Spanish multicenter study of bloodstream infections (19,30) and control

show abstract

First detection in Europe of the metallo-β-lactamase IMP-15 in clinical strains of Pseudomonas putida and Pseudomonas aeruginosa

Cited by 30 publications

References 20 publications

Multidrug-Resistant Sequence Type 235 Pseudomonas aeruginosa Clinical Isolates Producing IMP-26 with Increased Carbapenem-Hydrolyzing Activities in Vietnam

Multidrug-Resistant Sequence Type 235 Pseudomonas aeruginosa Clinical Isolates Producing IMP-26 with Increased Carbapenem-Hydrolyzing Activities in Vietnam

Bacteremia in a human caused by an XDR strain of Pseudomonas fulva

Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones

Contact Info

Product

Resources

About